Comparative pharmacokinetics of Aspegic 1000 mg i.v. versus 1000 mg i.m. thrice daily

  • B. Nia
  • J. M. Vergnaud
Article
Received:

Summary

The comparative pharmacokinetics of Aspegic, the lysine salt of acetylsalicylic acid, administered in multi doses either through i.v. or i.m. route was studied. 1 g of drug was injected each time with a frequency of 3 times a day. The pharmacokinetic parameters were determined using the experimental data in the literature. From these results, three categories of patients were considered, depending on their response to the drug. A numerical model was established in order to evaluate the following results: the drug level in the blood compartment obtained with the i.v. or i.m. administration, as well as the area under the curve for the first day and the third day when the so-called stationary state was obtained. Approximately similar values for AUC were obtained for each route of administration, for a given category of patients. The effect of the inter-variability of the patients characterised by their response to the drug was found to be of prime importance.

Keywords

Modelling Aspegic i.v./i.m. comparison pharmacokinetics single and multiple dose 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bannwarth B., Demotes-Mainard F., Schaeverke T., Labat L., Dehais J. (1995) Central analgesic effects of aspirin-like drugs. Fundam. Clin. Pharmacol., 9, 1–17.CrossRefPubMedGoogle Scholar
  2. 2.
    Henry P., Hiesse-Prevost O., Dillenschneider A., Ganry H., Insuasty J. (1983): Efficacy and tolerance of effervescent aspirin-metoclopramide association in the treatment of migraine attack. La presse Medicale, 24, 254–258.Google Scholar
  3. 3.
    Castaneda-Hemandez G., Castillo-Mendez M.S., Lopez-Munoz F.J., Granados-Soto V., Flores-Murietta F.J. (1994): Potentiation by caffeine of the analgesic effect of aspirin in the pain-induced functional impaiment model in the rat. Can. J. Physiol. Pharmacol., 72, 1127–1131.Google Scholar
  4. 4.
    Forster C., Anton F., Reek P.W., Weber E., Handwerker H.O. (1988): Measurement of the analgesic effects of aspirin with a new experimental analgesimetric procedure. Pain, 32, 215–222.CrossRefPubMedGoogle Scholar
  5. 5.
    Derumeaux G., Mouton-Schleifer D., Soyer R., Saoudi N. Cribier A., Letac B. (1995): High incidence of left atrial thrombus detected by transoesophageal endocardiography in heart transplant recipients. Eur. Heart. J., 16, 120–125.PubMedGoogle Scholar
  6. 6.
    Henneken C.H. (1990): Role of aspirin with thrombolytic therapy in acute myocardial infarction. Chest, 97, 1515–1555.Google Scholar
  7. 7.
    Rudra A. (1989): Injectable aspirin: attenuation of the cardiovascular response to tracheal intubation. Calcutta Med. J. 5, 39–42. antihypertensive effect of aspirin in rats. Br. J. Pharmacol., 94, 755-758.Google Scholar
  8. 9.
    Willerson J.T., Mueller S.D., Ferguson J.J. (1992): Should all patients with risk factors for ischemic heart disease receive aspirin. Texas Heart Inst. J., 19, 73–78.Google Scholar
  9. 10.
    Duc J., Pecoud A. (1988): About one case of respiratory arrest: aspirin and non steroidal anti-inflammatory drugs tolerance. Med. Hygiene, 46, 705–709.Google Scholar
  10. 11.
    De Gaetano G., Cerletti C. (1988): Prolonging of bleeding time by aspirin: a dual mechanism. Thrombosis Res., 50, 907–912.CrossRefGoogle Scholar
  11. 12.
    Gay W.A.J.R. (1990): Aspirin, blood loss and transfusion. Ann. Thorac. Surg., 50, 345.CrossRefPubMedGoogle Scholar
  12. 13.
    Van Gijn J. (1992): Aspirin: dose and indications in modern stroke preventions. Neurol. Clinics, 10, 193–207Google Scholar
  13. 14.
    Pappas J.M., Westengard J.C., Bull B.S. (1976): Population variability in the effect of aspirin on platelet function: implications for clinical trials and therapy. Arch. Pathol. Lab. Med., 118, 801–804.Google Scholar
  14. 15.
    Shah A., Lettieri J., Kaiser L., Echols R., Heller A.H. (1994): Comparative pharmacokinetics and safety of ciprofloxacin 400 mg i.v. thrice daily versus 750 mg p.o. twice daily. J. Antimicrob. Chemother., 33, 795–801.CrossRefPubMedGoogle Scholar
  15. 16.
    Catchpole C., Andrews J.M., Woodcock J., Wise R. (1994): The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg. i.v. and 750 mg p.o.. J Antimicrob. Chemother., 33, 103–110.CrossRefPubMedGoogle Scholar
  16. 17.
    Vergnaud J. M. (1993): Controlled Drug Release of oral Dosage Forms. E. Horwood, chapters 10–15.Google Scholar
  17. 18.
    Warembourg H., Delbecque H., Fruchart J.Ch. (1975): Dosage de la salicylèmie chez l’homme après administration d’acetylsalicylate de lysine par voie intraveineuse et par voie intramusculaire. Lille Med., 20, 923–927.PubMedGoogle Scholar
  18. 19.
    Warembourg H., Delbecque H., Ducloux G (1974): Appreciation des effets d’un sel injectable de l’acide acetylsalicyque chez des malades soumis à des traitements anticoagulants. Lille Med., 21, 632–638.Google Scholar
  19. 20.
    Vidal, Editions du Vidal, Paris (1994) Aspegic, 112.Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • B. Nia
    • 1
  • J. M. Vergnaud
    • 1
  1. 1.Laboratoire de Chimie des Materiaux et Chimie Industrielle, Faculté de Sciences et TechiquesUniversité de Saint EtienneSaint-Etienne cédex 2France

Personalised recommendations